News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

23

September

2026

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Read More
17

September

2026

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Read More
11

September

2026

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Read More
8

September

2026

Clearmind Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following...
Read More
4

September

2026

Clearmind Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Read More
1

September

2026

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Read More
24

August

2026

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support
Read More
13

August

2026

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Read More
11

August

2026

Clearmind Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention ...
Read More
6

August

2026

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Read More
3

August

2026

Clearmind Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems...
Read More
30

July

2026

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability in Part A of its Clinical Trial
Read More
20

July

2026

Clearmind Expands Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion...
Read More
17

July

2026

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Read More
16

July

2026

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Read More